vs

Side-by-side financial comparison of Burford Capital Ltd (BUR) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Burford Capital Ltd is the larger business by last-quarter revenue ($33.4M vs $19.6M, roughly 1.7× STANDARD BIOTOOLS INC.). Burford Capital Ltd runs the higher net margin — -112.2% vs -177.4%, a 65.2% gap on every dollar of revenue. STANDARD BIOTOOLS INC. produced more free cash flow last quarter ($-23.1M vs $-29.3M).

Burford Capital is a financial services company that provides specialized finance to the legal market. Founded in 2009, it offers financing to corporate legal departments and law firms engaged in litigation and arbitration, asset recovery and other legal finance and advisory activities. It operates internationally with headquarters in Guernsey.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BUR vs LAB — Head-to-Head

Bigger by revenue
BUR
BUR
1.7× larger
BUR
$33.4M
$19.6M
LAB
Higher net margin
BUR
BUR
65.2% more per $
BUR
-112.2%
-177.4%
LAB
More free cash flow
LAB
LAB
$6.2M more FCF
LAB
$-23.1M
$-29.3M
BUR

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BUR
BUR
LAB
LAB
Revenue
$33.4M
$19.6M
Net Profit
$-37.5M
$-34.7M
Gross Margin
48.5%
Operating Margin
-37.9%
-168.5%
Net Margin
-112.2%
-177.4%
Revenue YoY
-11.5%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.16
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BUR
BUR
LAB
LAB
Q4 25
$33.4M
Q3 25
$69.8M
$19.6M
Q2 25
$191.3M
$21.8M
Q1 25
$118.9M
$40.8M
Q3 24
$159.7M
$22.1M
Q2 24
$44.3M
$22.5M
Q1 24
$45.5M
Q4 23
$28.2M
Net Profit
BUR
BUR
LAB
LAB
Q4 25
$-37.5M
Q3 25
$-19.2M
$-34.7M
Q2 25
$88.3M
$-33.5M
Q1 25
$30.9M
$-26.0M
Q3 24
$53.7M
$-26.9M
Q2 24
$-29.9M
$-45.7M
Q1 24
$-32.2M
Q4 23
$-19.8M
Gross Margin
BUR
BUR
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Q4 23
47.6%
Operating Margin
BUR
BUR
LAB
LAB
Q4 25
-37.9%
Q3 25
35.5%
-168.5%
Q2 25
74.3%
-118.1%
Q1 25
65.4%
-80.8%
Q3 24
76.1%
-120.9%
Q2 24
32.0%
-134.5%
Q1 24
-132.2%
Q4 23
-75.9%
Net Margin
BUR
BUR
LAB
LAB
Q4 25
-112.2%
Q3 25
-27.4%
-177.4%
Q2 25
46.2%
-153.7%
Q1 25
26.0%
-63.8%
Q3 24
33.7%
-122.0%
Q2 24
-67.6%
-203.3%
Q1 24
-70.6%
Q4 23
-70.2%
EPS (diluted)
BUR
BUR
LAB
LAB
Q4 25
$-0.16
Q3 25
$-0.09
$-0.09
Q2 25
$0.39
$-0.09
Q1 25
$0.14
$-0.07
Q3 24
$0.24
$-0.07
Q2 24
$-0.14
$-0.12
Q1 24
$-0.27
Q4 23
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BUR
BUR
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$943.5M
$129.4M
Total DebtLower is stronger
$2.1B
Stockholders' EquityBook value
$2.4B
$399.7M
Total Assets
$6.6B
$539.6M
Debt / EquityLower = less leverage
0.87×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BUR
BUR
LAB
LAB
Q4 25
$943.5M
Q3 25
$677.7M
$129.4M
Q2 25
$372.2M
$158.6M
Q1 25
$486.6M
$150.9M
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Total Debt
BUR
BUR
LAB
LAB
Q4 25
$2.1B
Q3 25
$2.1B
Q2 25
$1.8B
Q1 25
$1.8B
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Stockholders' Equity
BUR
BUR
LAB
LAB
Q4 25
$2.4B
Q3 25
$2.5B
$399.7M
Q2 25
$2.5B
$424.5M
Q1 25
$2.4B
$454.6M
Q3 24
$3.2B
$489.3M
Q2 24
$3.1B
$510.3M
Q1 24
$577.3M
Q4 23
$-148.1M
Total Assets
BUR
BUR
LAB
LAB
Q4 25
$6.6B
Q3 25
$6.7B
$539.6M
Q2 25
$6.3B
$557.0M
Q1 25
$6.2B
$579.6M
Q3 24
$681.5M
Q2 24
$708.7M
Q1 24
$777.7M
Q4 23
$323.1M
Debt / Equity
BUR
BUR
LAB
LAB
Q4 25
0.87×
Q3 25
0.86×
Q2 25
0.71×
Q1 25
0.72×
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BUR
BUR
LAB
LAB
Operating Cash FlowLast quarter
$-29.0M
$-22.2M
Free Cash FlowOCF − Capex
$-29.3M
$-23.1M
FCF MarginFCF / Revenue
-87.7%
-118.1%
Capex IntensityCapex / Revenue
0.8%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$21.4M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BUR
BUR
LAB
LAB
Q4 25
$-29.0M
Q3 25
$-20.1M
$-22.2M
Q2 25
$-84.2M
$-20.7M
Q1 25
$155.2M
$-30.3M
Q3 24
$-97.4M
$-27.9M
Q2 24
$53.0M
$-39.0M
Q1 24
$-62.5M
Q4 23
$-14.1M
Free Cash Flow
BUR
BUR
LAB
LAB
Q4 25
$-29.3M
Q3 25
$-20.1M
$-23.1M
Q2 25
$-84.3M
$-22.6M
Q1 25
$155.1M
$-35.3M
Q3 24
$-97.4M
$-30.1M
Q2 24
$52.9M
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
FCF Margin
BUR
BUR
LAB
LAB
Q4 25
-87.7%
Q3 25
-28.8%
-118.1%
Q2 25
-44.1%
-103.6%
Q1 25
130.5%
-86.6%
Q3 24
-61.0%
-136.4%
Q2 24
119.5%
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Capex Intensity
BUR
BUR
LAB
LAB
Q4 25
0.8%
Q3 25
0.1%
4.5%
Q2 25
0.1%
8.7%
Q1 25
0.0%
12.4%
Q3 24
0.0%
10.2%
Q2 24
0.1%
8.6%
Q1 24
1.7%
Q4 23
0.3%
Cash Conversion
BUR
BUR
LAB
LAB
Q4 25
Q3 25
Q2 25
-0.95×
Q1 25
5.02×
Q3 24
-1.81×
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BUR
BUR

Principal Finance Segment$29.1M87%
Other$3.5M10%
Management Fee Income$878.0K3%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons